Editor’s Note: The following article was based on published research that has recently been retracted by The Lancet due to concerns over data integrity. The full retraction statement can be found here. A multinational observational study evaluating the use of hydroxychloroquine or chloroquine, either as monotherapy or with a macrolide, found that these treatments may increase…
Authors call for increased awareness of need for treatment with secondary preventive medications.
Mavacamten is a novel, oral, selective allosteric inhibitor of cardiac myosin. It works by inhibiting excessive myosin-actin cross-bridge formation, thereby reducing excessive cardiac muscle contractility and increasing diastolic compliance.
The FDA has granted Fast Track designation to omecamtiv mecarbil (Amgen) for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).
The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction with and without type 2 diabetes
Concurrent treatment with azithromycin linked to greater changes in corrected QT interval.
The Agency is warning the public that the use of these agents should be limited to clinical trial settings or for treating certain hospitalized patients under the Emergency Use Authorization.
Presentation variable with high prevalence of nonobstructive disease, poor prognosis.
Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.
Most patients had very low eosinophils on admission; common symptoms include fever, shortness of breath.
